The FDA just approved a new painkiller. Is it too good to be true?
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...
Top Wall Street Forecasters Revamp Vertex Pharmaceuticals Price Expectations Ahead Of Q4 Earnings
Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...
pharmaphorum6h
Share in cystic fibrosis firm Sionna rise sharply after IPO
Sionna Therapeutics has closed its initial public offering, raising $191 million for its pipeline of therapies for cystic ...
Hosted on MSN1d
Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.
Wall Street week ahead: Investors’ focus on Trump’s reciprocal tariffs, inflation data, Jerome Powell’s testimony
The focus of Wall Street investors in the week ahead will be primarily on expected reciprocal trade tariffs by US President ...
2 Biotech Stocks to Buy Hand Over Fist in February
Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the strategy for long-term investors remains the same: Invest in companies that can perform ...